• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; TISSUE, HEART-VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; TISSUE, HEART-VALVE Back to Search Results
Model Number 11500A
Device Problems Gradient Increase (1270); Difficult to Open or Close (2921); Patient Device Interaction Problem (4001)
Patient Problem Insufficient Information (4580)
Event Date 09/27/2021
Event Type  Injury  
Manufacturer Narrative
Pannus overgrowth, or host tissue, is considered to be a form of non-structural valve dysfunction.The growth of host tissue on the sewing ring is expected and is a natural part of the healing reaction to prosthesis implantation.Pannus can have both beneficial and harmful effects depending on the amount of growth.A small amount of host tissue growth over the suture line is needed to form a non-thrombogenic surface and complete the healing process after valve implantation.In contrast, if there is an excessive amount of pannus growth, it can extend onto the cusp surfaces leading to thickening of the cusps, leaflet immobility, elevated gradients, and stenosis.Host tissue growth can also contribute to cusp retraction or curling resulting in valvular regurgitation.The device was returned and product evaluation is ongoing.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.
 
Event Description
Edwards received information that a 19mm aortic pericardial valve, implanted approximately one (1) year and ten (10) months, was explanted due to aortic stenosis secondary to leaflet immobility caused by pannus growth.The device was explanted and replaced with a non-edwards valve with no adverse events.The patient status was reported as recovered.The doctor commented that this explant was device related.
 
Manufacturer Narrative
H10: additional narratives.Updated d4, h4, and h6 per new information received.The root cause of this event cannot be conclusively determined.However, it is likely that patient related factors and the progression of the underlying valvular disease pathology contributed to the event.The device history record (dhr) was reviewed and showed that this device met all manufacturing and sterilization specifications for product release prior to distribution.No issues were identified that would have impacted this event.Edwards will continue to review and monitor all events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Manufacturer Narrative
H3: device evaluated by manufacturer : customer reports of stenosis, leaflet immobility, and pannus growth were confirmed.The x-ray demonstrated the wireform and cocr band remained intact; the vfit cocr alloy band was not expanded.Moderate host tissue overgrowth encroached onto the tissue and into the orifice at the greatest distance of approximately 10mm on leaflet 2 at the inflow aspect.Host tissue overgrowth on the stent circumference was minimal at the outflow aspect.Host tissue overgrowth restricted leaflet mobility and led to stenosis.All three leaflets were swollen along the free margin near commissures 1 and 2.Wireform was exposed on commissures 1 and 3.Serrated mechanical damage marks were observed on the outflow surfaces of leaflets 1 and 3 at commissure 1.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS INSPIRIS RESILIA AORTIC VALVE
Type of Device
TISSUE, HEART-VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer Contact
gail warner
one edwards way
mailstop 6.1 anton
irvine, CA 92614
9492504096
MDR Report Key12682601
MDR Text Key278426105
Report Number2015691-2021-05868
Device Sequence Number1
Product Code LWR
UDI-Device Identifier00690103198867
UDI-Public(01)00690103198867(17)201106
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150048
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 12/21/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date11/06/2020
Device Model Number11500A
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer10/13/2021
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 09/27/2021
Initial Date FDA Received10/22/2021
Supplement Dates Manufacturer Received11/01/2021
12/20/2021
Supplement Dates FDA Received11/23/2021
12/20/2021
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured11/07/2018
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Life Threatening; Hospitalization; Required Intervention;
Patient Age70 YR
Patient SexFemale
-
-